Human epidermal growth factor receptor 2 (HER2) positive breast carcinomas due to HER2 amplification are associated with aggressive behavior and a poor prognosis. Anti-HER2-targeted therapies are widely used to treat HER2-positive breast carcinomas with excellent outcomes. Accurate identification of HER2...
Compared to luminal subtypes, Basal-like and HER2-enriched subtypes present worse five-year prognosis, and the HER2-enriched subtype has the worst relapse-free survival5. Several lines of evidence indicate that the most representative breast tumor subtype phenotypes identified by mRNA intrinsic ...
https://www.bls.gov/data/inflation_calculator.htm 34. Wapnir IL, Price KN, Anderson SJ, et al; International Breast Cancer Study Group; NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists’ Group; Breast International Group. Efficacy of chemotherapy ...
3.7. Residual Cancer Burden 3.7.1. Consensus Statements Residual cancer burden (RCB) after neoadjuvant treatment is a feature correlated to the risk of relapse in surgically resected HR+/HER2− eBC; A high RCB is associated with a worse prognosis and RCB-III identifies patients at the highest...
The diagnosis of breast cancer with high HER2 expression levels is associated with a worse prognosis and more dynamic disease progression. Significant improvements in therapy outcomes for this biologic subtype were achieved when HER2 blockers were introduced into routine management [24,25]. Improved ...